Search results
Results from the WOW.Com Content Network
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
RDW-SD is calculated as the width (in fL) of the RBC size distribution histogram at the 20% height level. This parameter is, therefore, not influenced by the average RBC size (mean corpuscular volume, MCV). [7] RDW-CV (expressed in %) is calculated with the following formula: RDW-CV = (1 standard deviation of RBC volume ÷ MCV) × 100%. [8]
Maintenance chemotherapy is a repeated low-dose treatment to prolong remission. [5] [6]: 55–59 Salvage chemotherapy or palliative chemotherapy is given without curative intent, but simply to decrease tumor load and increase life expectancy. For these regimens, in general, a better toxicity profile is expected. [6]: 55–59
Drug Manufacturer Indication Adagrasib: In combination with cetuximab for the treatment of adults with KRAS G12C mutated locally advanced or metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy [2]
The trial tested 230 patients whose cancer does not express a protein known as CD30 and returns after a period of remission or does not respond to treatment. The drug, when compared to a ...
Antileukemic drugs, anticancer drugs that are used to treat one or more types of leukemia, include: [1] 6-Mercaptopurine; 6-Thioguanine; Arsenic trioxide; Asparaginase;
(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge ...